<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="correction" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Exp Clin Cancer Res</journal-id><journal-id journal-id-type="iso-abbrev">J Exp Clin Cancer Res</journal-id><journal-title-group><journal-title>Journal of Experimental &#x00026; Clinical Cancer Research : CR</journal-title></journal-title-group><issn pub-type="ppub">0392-9078</issn><issn pub-type="epub">1756-9966</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39731134</article-id><article-id pub-id-type="pmc">PMC11681660</article-id><article-id pub-id-type="publisher-id">3257</article-id><article-id pub-id-type="doi">10.1186/s13046-024-03257-8</article-id><article-categories><subj-group subj-group-type="heading"><subject>Correction</subject></subj-group></article-categories><title-group><article-title>Correction: Single-cell deconvolution algorithms analysis unveils autocrine IL11-mediated resistance to docetaxel in prostate cancer via activation of the JAK1/STAT4 pathway</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Cheng</surname><given-names>Bisheng</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Li</surname><given-names>Lingfeng</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Luo</surname><given-names>Tianlong</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Wang</surname><given-names>Qiong</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Luo</surname><given-names>Yong</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Bai</surname><given-names>Shoumin</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Li</surname><given-names>Kaiwen</given-names></name><address><email>likw6@mail.sysu.edu.cn</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Lai</surname><given-names>Yiming</given-names></name><address><email>laiym3@mail.sysu.edu.cn</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-2013-073X</contrib-id><name><surname>Huang</surname><given-names>Hai</given-names></name><address><email>huangh9@mail.sysu.edu.cn</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01px77p81</institution-id><institution-id institution-id-type="GRID">grid.412536.7</institution-id><institution-id institution-id-type="ISNI">0000 0004 1791 7851</institution-id><institution>Department of Urology, </institution><institution>Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, </institution></institution-wrap>Guangzhou, 510120 China </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01px77p81</institution-id><institution-id institution-id-type="GRID">grid.412536.7</institution-id><institution-id institution-id-type="ISNI">0000 0004 1791 7851</institution-id><institution>Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, </institution><institution>Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, </institution></institution-wrap>Guangzhou, 510120 China </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01px77p81</institution-id><institution-id institution-id-type="GRID">grid.412536.7</institution-id><institution-id institution-id-type="ISNI">0000 0004 1791 7851</institution-id><institution>Guangdong Provincial Clinical Research Center for Urological Diseases, </institution><institution>Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, </institution></institution-wrap>Guangzhou, 510120 China </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00zat6v61</institution-id><institution-id institution-id-type="GRID">grid.410737.6</institution-id><institution-id institution-id-type="ISNI">0000 0000 8653 1072</institution-id><institution>Department of Urology, </institution><institution>The Sixth Afliated Hospital of Guangzhou Medical University, Qingyuan People&#x02019;s Hospital, </institution></institution-wrap>Qingyuan, 511518 Guangdong China </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01eq10738</institution-id><institution-id institution-id-type="GRID">grid.416466.7</institution-id><institution-id institution-id-type="ISNI">0000 0004 1757 959X</institution-id><institution>Department of Urology, </institution><institution>Nanfang Hospital, Southern Medical University, </institution></institution-wrap>Guangzhou, 511430 China </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01px77p81</institution-id><institution-id institution-id-type="GRID">grid.412536.7</institution-id><institution-id institution-id-type="ISNI">0000 0004 1791 7851</institution-id><institution>Department of Radiation Oncology, </institution><institution>Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, </institution></institution-wrap>Guangzhou, 510120 China </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/055gkcy74</institution-id><institution-id institution-id-type="GRID">grid.411176.4</institution-id><institution-id institution-id-type="ISNI">0000 0004 1758 0478</institution-id><institution>Department of Urology, </institution><institution>Fujian Medical University Union Hospital, </institution></institution-wrap>Fuzhou, China </aff></contrib-group><pub-date pub-type="epub"><day>28</day><month>12</month><year>2024</year></pub-date><pub-date pub-type="pmc-release"><day>28</day><month>12</month><year>2024</year></pub-date><pub-date pub-type="collection"><year>2024</year></pub-date><volume>43</volume><elocation-id>333</elocation-id><permissions><copyright-statement>&#x000a9; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.</license-p></license></permissions><related-article related-article-type="corrected-article" ext-link-type="doi" xlink:href="10.1186/s13046-024-02962-8" id="d33e50"/><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Italian National Cancer Institute &#x02018;Regina Elena&#x02019; 2024</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p id="Par1">
<bold>Correction:&#x000a0;J Exp Clin Cancer Res 43, 67 (2024)</bold>
</p><p id="Par2">
<bold>https://doi.org/10.1186/s13046-024-02962-8</bold>
</p><p id="Par3">Following the publication of the original article [<xref ref-type="bibr" rid="CR1">1</xref>], the authors identified an inadvertent duplication of images in Figure 4G due to oversight during manuscript preparation</p><p id="Par4">The correct figure is presented below:</p><p id="Par5"><bold>Incorrect Fig.</bold>&#x000a0;<xref rid="Fig1" ref-type="fig">4</xref><fig id="Fig1"><label>Fig.&#x000a0;4</label><caption><p>IL-11 contributes to increased viability and chemoresistance in prostate cancer cells. <bold>A</bold> Western blot analyses displaying the dose-dependent expression of IL-11 and IL-11RA in prostate cancer cell lines PC3 and DU145 after treatment with various concentrations of docetaxel (DTX) for 48 h. <bold>B</bold> ELISA measuring IL-11 secretion in the prostate cancer cell lines PC3 and DU145 with or without DTX treatment(1 nM for 48 h). The error bars indicate the standard deviations of three experiments independently. <bold>C</bold> Line graphs representing the percentage of cell viability over a period of 6 days for prostate cancer cell lines PC3 and DU145, comparing the efects of IL-11 overexpression against the control. <bold>D</bold> Images of colony formation in prostate cancer cell lines PC3 and DU145, comparing the control and overexpression treated groups, alongside bar graphs quantifying the number of colonies formed, indicating a signifcant increase in colony formation upon IL-11 treatment. <bold>E</bold> Graphs plotting cell viability percentages against a range of DTX concentrations for prostate cancer cell lines PC3 and DU145, comparing control groups to those treated with IL-11 overexpression.<bold> F</bold> Graphs depicting the efect of recombinant human interleukin 11(RhIL-11) on the cell viability of prostate cancer cell lines PC3 and DU145 at various DTX concentrations compared to the DMSO control. <bold>G</bold>, H Microscopy images of prostate cancer cell lines PC3 (<bold>G</bold>) and DU145 (<bold>H</bold>) displaying live (green) and dead (red) cells in the control and IL-11-treated groups, as indicated by bright feld and fuorescence staining (<bold>I, J</bold>). Bar graphs showing the percentage of dead cells in prostate cancer cell lines PC3 (<bold>I</bold>) and DU145 (<bold>J</bold>), comparing the control and IL-11-treated groups. *<italic>P</italic>&#x0003c;0.05, **<italic>P</italic>&#x0003c;0.01, ***<italic>P</italic>&#x0003c;0.001</p></caption><graphic xlink:href="13046_2024_3257_Fig1_HTML" id="MO1"/></fig></p><p id="Par6"><bold>Correct Fig.</bold>&#x000a0;<xref rid="Fig2" ref-type="fig">4</xref><fig id="Fig2"><label>Fig.&#x000a0;4</label><caption><p>IL-11 contributes to increased viability and chemoresistance in prostate cancer cells. <bold>A</bold> Western blot analyses displaying the dose-dependent expression of IL-11 and IL-11RA in prostate cancer cell lines PC3 and DU145 after treatment with various concentrations of docetaxel (DTX) for 48 h. <bold>B</bold> ELISA measuring IL-11 secretion in the prostate cancer cell lines PC3 and DU145 with or without DTX treatment(1 nM for 48 h). The error bars indicate the standard deviations of three experiments independently. <bold>C</bold> Line graphs representing the percentage of cell viability over a period of 6 days for prostate cancer cell lines PC3 and DU145, comparing the efects of IL-11 overexpression against the control. <bold>D</bold> Images of colony formation in prostate cancer cell lines PC3 and DU145, comparing the control and overexpression treated groups, alongside bar graphs quantifying the number of colonies formed, indicating a signifcant increase in colony formation upon IL-11 treatment. <bold>E</bold> Graphs plotting cell viability percentages against a range of DTX concentrations for prostate cancer cell lines PC3 and DU145, comparing control groups to those treated with IL-11 overexpression.<bold> F</bold> Graphs depicting the efect of recombinant human interleukin 11(RhIL-11) on the cell viability of prostate cancer cell lines PC3 and DU145 at various DTX concentrations compared to the DMSO control. <bold>G</bold>, H Microscopy images of prostate cancer cell lines PC3 (<bold>G</bold>) and DU145 (<bold>H</bold>) displaying live (green) and dead (red) cells in the control and IL-11-treated groups, as indicated by bright feld and fuorescence staining (<bold>I, J</bold>). Bar graphs showing the percentage of dead cells in prostate cancer cell lines PC3 (<bold>I</bold>) and DU145 (<bold>J</bold>), comparing the control and IL-11-treated groups. *<italic>P</italic>&#x0003c;0.05, **<italic>P</italic>&#x0003c;0.01, ***<italic>P</italic>&#x0003c;0.001</p></caption><graphic xlink:href="13046_2024_3257_Fig2_HTML" id="MO2"/></fig></p><p id="Par7">The correction does not compromise the validity of the conclusions and the overall content of the article. The original article [<xref ref-type="bibr" rid="CR1">1</xref>] has been updated.</p></body><back><fn-group><fn><p>Bisheng Cheng, Lingfeng Li, Tianlong Luo and Qiong Wang contributed equally to this work.</p></fn></fn-group><ref-list id="Bib1"><title>Reference</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>B</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Luo</surname><given-names>T</given-names></name><etal/></person-group><article-title>Single-cell deconvolution algorithms analysis unveils autocrine IL11-mediated resistance to docetaxel in prostate cancer via activation of the JAK1/STAT4 pathway</article-title><source>J Exp Clin Cancer Res</source><year>2024</year><volume>43</volume><fpage>67</fpage><pub-id pub-id-type="doi">10.1186/s13046-024-02962-8</pub-id><pub-id pub-id-type="pmid">38429845</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Cheng B, Li L, Luo T, et al. Single-cell deconvolution algorithms analysis unveils autocrine IL11-mediated resistance to docetaxel in prostate cancer via activation of the JAK1/STAT4 pathway. J Exp Clin Cancer Res. 2024;43:67. 10.1186/s13046-024-02962-8.<pub-id pub-id-type="pmid">38429845</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>